12.01
price up icon0.25%   0.03
after-market アフターアワーズ: 12.11 0.10 +0.83%
loading
前日終値:
$11.98
開ける:
$11.83
24時間の取引高:
790.76K
Relative Volume:
0.52
時価総額:
$1.24B
収益:
-
当期純損益:
$-135.21M
株価収益率:
-8.3921
EPS:
-1.4311
ネットキャッシュフロー:
$-114.35M
1週間 パフォーマンス:
-10.84%
1か月 パフォーマンス:
-6.61%
6か月 パフォーマンス:
+35.40%
1年 パフォーマンス:
-14.94%
1日の値動き範囲:
Value
$11.80
$12.43
1週間の範囲:
Value
$11.56
$13.62
52週間の値動き範囲:
Value
$7.23
$14.68

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name
名前
Oric Pharmaceuticals Inc
Name
セクター
Healthcare (1060)
Name
電話
(650) 388-5600
Name
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Name
職員
104
Name
Twitter
Name
次回の収益日
2026-11-12
Name
最新のSEC提出書
Name
ORIC's Discussions on Twitter

Compare ORIC vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ORIC icon
ORIC
Oric Pharmaceuticals Inc
12.01 1.36B 0 -135.21M -114.35M -1.4311
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
505.64 127.93B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
196.48 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
742.12 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
928.44 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
200.87 43.93B 742.00K -1.37B -1.07B -7.0731

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-06-12 再開されました Stifel Buy
2026-05-15 アップグレード Goldman Neutral → Buy
2026-01-07 開始されました Piper Sandler Overweight
2025-11-20 開始されました Evercore ISI Outperform
2025-11-18 開始されました Wolfe Research Peer Perform
2025-09-04 再開されました Guggenheim Buy
2025-07-08 開始されました Ladenburg Thalmann Buy
2024-10-31 開始されました Wells Fargo Overweight
2024-09-06 開始されました Stifel Buy
2024-02-23 開始されました Cantor Fitzgerald Overweight
2023-09-22 開始されました Wedbush Outperform
2023-03-23 アップグレード H.C. Wainwright Neutral → Buy
2023-03-21 アップグレード Guggenheim Neutral → Buy
2023-03-16 アップグレード Oppenheimer Perform → Outperform
2022-07-18 再開されました Oppenheimer Perform
2022-04-04 アップグレード Citigroup Neutral → Buy
2022-03-25 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-22 ダウングレード Citigroup Buy → Neutral
2022-03-22 ダウングレード Guggenheim Buy → Neutral
2022-03-22 ダウングレード Oppenheimer Outperform → Perform
2021-07-06 アップグレード Citigroup Neutral → Buy
2021-01-25 ダウングレード Citigroup Buy → Neutral
2020-08-13 開始されました Robert W. Baird Outperform
2020-08-06 アップグレード Citigroup Neutral → Buy
2020-08-03 開始されました H.C. Wainwright Buy
2020-05-19 開始されました Citigroup Neutral
2020-05-19 開始されました Guggenheim Buy
2020-05-19 開始されました JP Morgan Overweight
2020-05-19 開始されました Jefferies Buy
すべてを表示

Oric Pharmaceuticals Inc (ORIC) 最新ニュース

pulisher
Oct 01, 2026

Form 144 Oric Pharmaceuticals For: 1 October By Investing.com - Investing.com Canada

Oct 01, 2026
pulisher
Sep 29, 2026

ORIC Pharmaceuticals (ORIC) CFO Dominic Piscitelli Sells 13,400 Shares - GuruFocus

Sep 29, 2026
pulisher
Sep 29, 2026

Taxes of Oric Pharmaceuticals, Inc. – HAN:4TZ - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $181,302.00 in Stock - MarketBeat

Sep 29, 2026
pulisher
Sep 29, 2026

Oric Pharma CFO sells $181k in shares By Investing.com - Investing.com South Africa

Sep 29, 2026
pulisher
Sep 29, 2026

Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026
pulisher
Sep 29, 2026

Oric Pharma CFO sells $181k in shares - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

After a $4.36 option exercise, Oric Pharmaceuticals (ORIC) CFO sells 13,400 shares. - Stock Titan

Sep 29, 2026
pulisher
Sep 29, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18 - MarketBeat

Sep 29, 2026
pulisher
Sep 26, 2026

1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE - MarketBeat

Sep 26, 2026
pulisher
Sep 25, 2026

ORIC Pharmaceuticals CFO Dominic Piscitelli Sells 600 Shares of ORIC Stock - GuruFocus

Sep 25, 2026
pulisher
Sep 25, 2026

Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares By Investing.com - Investing.com Australia

Sep 25, 2026
pulisher
Sep 25, 2026

Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares - Investing.com

Sep 25, 2026
pulisher
Sep 25, 2026

Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026
pulisher
Sep 25, 2026

A finance chief exercised 600 options and sold 600 shares at Oric Pharmaceuticals (ORIC). - Stock Titan

Sep 25, 2026
pulisher
Sep 23, 2026

ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 23, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat

Sep 23, 2026
pulisher
Sep 23, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at BTIG Research - MarketBeat

Sep 23, 2026
pulisher
Sep 23, 2026

BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Canada

Sep 23, 2026
pulisher
Sep 23, 2026

BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

ORIC Pharmaceuticals Initiates Coverage by BTIG -- Rating Set to Buy - GuruFocus

Sep 23, 2026
pulisher
Sep 22, 2026

(ORIC) Volatility Zones as Tactical Triggers - Stock Traders Daily

Sep 22, 2026
pulisher
Sep 19, 2026

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits

Sep 19, 2026
pulisher
Sep 18, 2026

Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.com.au

Sep 18, 2026
pulisher
Sep 18, 2026

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth - Moomoo

Sep 18, 2026
pulisher
Sep 18, 2026

Oric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotech - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Why ORIC Pharmaceuticals (ORIC) Is Back In The Spotlight - Simply Wall Street

Sep 17, 2026
pulisher
Sep 16, 2026

ORIC Pharmaceuticals Inc. (US68622P1093.SG) stock price, news, quote and history - Yahoo Finance UK

Sep 16, 2026
pulisher
Sep 15, 2026

ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch - AlphaStreet

Sep 15, 2026
pulisher
Sep 15, 2026

ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway - tradingview.com

Sep 15, 2026
pulisher
Sep 13, 2026

Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC - MarketBeat

Sep 13, 2026
pulisher
Sep 12, 2026

Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily

Sep 12, 2026
pulisher
Sep 10, 2026

ORIC: Advancing late-stage prostate and lung cancer programs with robust funding and global trials - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

ORIC: Phase III trials and robust funding position support late-stage oncology pipeline growth - TradingView

Sep 10, 2026
pulisher
Sep 09, 2026

ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union

Sep 09, 2026
pulisher
Sep 09, 2026

ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential - TradingView

Sep 09, 2026
pulisher
Sep 07, 2026

Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Sep 07, 2026
pulisher
Sep 07, 2026

Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView

Sep 07, 2026
pulisher
Sep 05, 2026

ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS

Sep 05, 2026
pulisher
Sep 04, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 04, 2026
pulisher
Sep 03, 2026

Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks

Sep 03, 2026
pulisher
Sep 02, 2026

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Sep 02, 2026
pulisher
Sep 02, 2026

ORIC stock holds firm as biotech valuation nears 0.93 billion USD - ad-hoc-news.de

Sep 02, 2026
pulisher
Sep 02, 2026

(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Sep 02, 2026
pulisher
Aug 31, 2026

Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - ad-hoc-news.de

Aug 31, 2026
pulisher
Aug 28, 2026

Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan

Aug 28, 2026
pulisher
Aug 28, 2026

Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing - Yahoo Finance

Aug 28, 2026
pulisher
Aug 26, 2026

ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan

Aug 26, 2026
pulisher
Aug 21, 2026

Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat

Aug 21, 2026

Oric Pharmaceuticals Inc (ORIC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Oric Pharmaceuticals Inc (ORIC) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Heyman Richard A.
Director
Oct 01 '26
Sale
12.91
3,500
45,199
38,300
Heyman Richard A.
Director
Oct 01 '26
Sale
12.91
3,200
41,325
203,472
$95.25
price down icon 0.50%
$34.75
price down icon 2.20%
$56.76
price up icon 0.57%
$224.41
price up icon 0.21%
ONC ONC
$364.02
price up icon 0.34%
$200.87
price up icon 0.50%
大文字化:     |  ボリューム (24 時間):